It’s Time to End Drug-Resistant Tuberculosis

  13 May 2019

Tuberculosis (TB) is an ancient disease that has killed over 2 billion people in the past 200 years. More recently, drug-resistant strains of TB which are resistant to one or more of the drugs normally used to treat it have emerged and spread. Drug-resistant TB (DR-TB) is the only major airborne drug-resistant epidemic. It is harder and more costly to treat than drug-susceptible TB (DSTB), and affects more than half a million people across the globe annually, mostly in low and middle income countries.

Healthy Animals  
Back

OUR UNDERWRITERS

Unrestricted financial support by:

Antimicrobial Resistance Fighter Coalition

Evotec

JSS University

INTERNATIONAL FEDERATION PHARMACEUTICAL MANUFACTURERS & ASSOCIATIONS





Technology Database

Display your AMR Technology, Product and Service

Suppliers and Users of Technologies, Products and Services benefit from CAPI.
CAPI (Continuous AMR Partnering Initiative) unites Suppliers and Users worldwide with the aim to add to the curbing of AMR.

Read more and make your own Technology Page >>
What is going on with AMR?
Stay tuned with remarkable global AMR news and developments!